SHANGHAI, April 23, 2015 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology and medical device industries, with operations in China and the United States, today announced that it will release financial results for the first quarter of 2015 after the New York Stock Exchange closes on Wednesday, May 13, 2015 (which will be Thursday morning, May 14, 2015 Shanghai time). The earnings release will be available on the investor relations section of the Company's website at http://www.wuxiapptec.com/.

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Thursday, May 14, 2015, to discuss the first-quarter 2015 financial results and recent business activities. The conference call may be accessed by calling:

Mainland China 4001 200 539

Hong Kong 800 905 927

Singapore 800 616 3222

United Kingdom 0800 015 9725

United States 1855 298 3404

United States-New York (toll) +1 631 5142 526

Other countries (toll) +65 6823 2299

Conference ID 7728019

A telephone replay will be available two hours after the call's completion at:

Mainland China 4001 842 240

Hong Kong 800 966 697

Singapore 800 616 2127

United Kingdom 0800 169 7301

United States 1866 846 0868

Conference ID 7728019

A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com/.

About WuXi PharmaTech

WuXi PharmaTech (NYSE: WX) is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology, and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For further information, please visit http://www.wuxiapptec.com .

For more information, please contact:

Ronald Aldridge

Director of Investor Relations

WuXi PharmaTech (Cayman) Inc.

Tel: +1-201-585-2048

Email: Ron_Aldridge@wuxiapptec.com

Web: http://www.wuxiapptec.com